Cara rounds up $15M for post-op pain drug

Connecticut-based Cara Therapeutics has landed $15 million in Series D financing with help from new investor Rho Ventures, which led the round. Cara is developing CR845, an intravenous post-operative pain treatment currently being studied in a Phase II clinical trial in women following laparoscopic hysterectomy. The financing will be used to support further clinical development of CR845. "There has been little innovation in post-operative pain treatment where opioid use continues to...